AQuA - 'Acquired Haemophilia A - National Audit'
Acquired haemophilia A is a rare, potentially life-threatening bleeding disorder caused by autoantibodies against FVIII. There are national BSH guidelines for the ‘Diagnosis and Management of Acquired Coagulation Factor Inhibitor’ from 2013, and international consensus recommendations from 2020, but management options have changed considerably over this time and local practices across the UK differ.
The HaemSTAR hub-and-spoke model is an ideal platform for looking at rare diseases. AQuA is a multicentre, national audit, comprising a 5-year retrospective review of patients diagnosed with acquired haemophilia A. We aim to include a minimum of 6 comprehensive care centres in the audit.
Please register your interest with study lead, Becks Shaw (r.shaw3@nhs.net)
We plan to ask sites to start the audit process approvals in the last quarter of 2025. Once local approvals are in place, we can provide access for REDCap data collection, with the aim to start data collection from Jan 2026.
Lay Summary
Acquired haemophilia A is a rare and serious bleeding condition. Although national and international guidelines exist, treatments have changed over time and care can vary between hospitals. This national audit will review how patients with acquired haemophilia A have been diagnosed and treated across the UK over the past five years, with the aim of understanding current practice and improving consistency of care.